ADC Therapeutics SA (ADCT) Tops Q2 EPS by 12c

ADC Therapeutics SA (NYSE: ADCT) reported Q2 EPS of ($0.58), $0.12 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $19.2 million versus the consensus estimate of $20.25 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• RXO shares soar as C.H. Robinson announces $5.8B cash and stock buyout
• AMD (AMD) Reiterated at Overweight by Cantor Fitzgerald on Potential Catalyst in Upcoming Earnings
• This multi-trillion stock is "cheap and getting cheaper": Morgan Stanley